

StemRIM Announces Nomination of Director Candidates, Audit & Supervisory Board Member Candidates, and Substitute Audit & Supervisory Board Member Candidate

Osaka, Japan, September 25, 2026 – StemRIM Inc. (TSE: 4599, President and CEO: Masatsune Okajima; “Company”) announces that its Board of Directors, at a meeting held today, resolved to nominate the following candidates for Directors, Audit & Supervisory Board Members, and a Substitute Audit & Supervisory Board Member to be submitted for approval at the 21st Annual General Meeting of Shareholders scheduled to be held on October 28, 2026.

1. Director Candidates

As the terms of office of all four current Directors will expire at the conclusion of the Annual General Meeting of Shareholders, the Company proposes the election of five Directors, increasing the number of Directors by one, in order to support future business expansion and strengthen its risk management framework. The Director candidates are as follows.

Name	Current Position	Status
Katsuto Tamai	Representative Director, Chairman of the Board and Chief Scientific Officer	Reelection
Masatsune Okajima	Representative Director, President and Chief Executive Officer	Reelection
Noriko Sawai	Outside Director	Reelection
Hirotsada Nagai	Outside Director	Reelection
Masaru Iida	—	New Nominee

Ms. Noriko Sawai, Mr. Hirotsada Nagai and Mr. Masaru Iida are candidates for Outside Director positions.

2. Audit & Supervisory Board Member Candidates

As the terms of office of all three current Audit & Supervisory Board Members will expire at the conclusion of the Annual General Meeting of Shareholders, the Company proposes the election of three Audit & Supervisory Board Members. The candidates are as follows.

Name	Current Position	Status
Akihiro Mizukami	Outside Audit & Supervisory Board Member	Reelection
Yoichiro Shimada	Outside Audit & Supervisory Board Member	Reelection
Kazuyoshi Okuhira	—	New Nominee

Mr. Akihiro Mizukami, Mr. Yoichiro Shimada and Mr. Kazuyoshi Okuhira are candidates for Outside Audit & Supervisory Board Member positions.

3. Substitute Audit & Supervisory Board Member Candidate

The Company proposes the election of one Substitute Audit & Supervisory Board Member in preparation for any circumstance in which the number of Audit & Supervisory Board Members falls below the number required by applicable laws and regulations. This proposal has received the consent of the Audit & Supervisory Board.

Name	Current Position	Status
Yoji Kudo	Full-time Outside Audit & Supervisory Board Member	New Nominee

Mr. Yoji Kudo is a candidate for Substitute Outside Audit & Supervisory Board Member.

4. Career Summaries of New Officer Candidates

(1) New Director Candidate

Masaru Iida (Date of Birth: February 15, 1967)

Date	Career Summary
Apr. 1989	Joined The Sumitomo Bank, Ltd. (currently Sumitomo Mitsui Banking Corporation)
May 1993	Completed the LL.M. Program at the University of Pennsylvania Law School
Apr. 1996	Deputy General Manager, Financial Products Development Department, The Sumitomo Bank, Ltd.
Apr. 2001	Deputy General Manager, Treasury Marketing Division, Sumitomo Mitsui Banking Corporation
Mar. 2008	Graduated from Hitotsubashi University Law School
Dec. 2009	Registered as Attorney-at-Law with the Dai-ichi Tokyo Bar Association
Jan. 2010	Joined Masuda & Partners Law Office
Jun. 2011	Outside Audit & Supervisory Board Member, DeNA Co., Ltd.
Jul. 2011	Representative Attorney, Iida Management Law Office (incumbent)
Jul. 2015	Supervisory Officer, Ichigo Hotel REIT Investment Corporation (incumbent)
Jun. 2019	Outside Audit & Supervisory Board Member, Exawizards Inc. (incumbent)

(2) New Audit & Supervisory Board Member Candidate

Kazuyoshi Okuhira (Date of Birth: May 1, 1961)

Date	Career Summary
Mar. 1984	Joined Charle Co., Ltd.
Apr. 2010	Auditor, Charle Rytac Co., Ltd.
Apr. 2012	Executive Officer, Charle Co., Ltd.
Jun. 2012	President and Representative Director, Charle Co., Ltd.
Oct. 2022	Joined MM Group Holdings Co., Ltd.
Oct. 2022	Executive Officer, Head of Strategic Business Headquarters and Chief Financial Officer, MM Group Holdings Co., Ltd.
Nov. 2023	Auditor, BJC Co., Ltd.
Dec. 2023	Auditor, CHARIS & Co., Ltd.
Oct. 2024	Director and Audit & Supervisory Committee Member, BJC Co., Ltd.
Aug. 2026	Advisor, StemRIM Inc. (incumbent)

(3) New Substitute Audit & Supervisory Board Member Candidate

Yoji Kudo (Date of Birth: October 20, 1948)

Date	Career Summary
Jun. 1975	Joined Uniroyal Inc. (U.S.), Overseas Business Division, Area Manager
Feb. 1985	Joined Eli Lilly Japan K.K., Arden Export Division, Section Manager
Oct. 1990	General Manager, West Japan Sales Division, Eli Lilly Japan K.K.
Sep. 1993	General Manager, Human Resources Department, Eli Lilly Japan K.K.
Sep. 1996	General Manager, Elanco Animal Health Division, Eli Lilly Japan K.K.
Jun. 1999	General Manager, Business Development Department, Eli Lilly Japan K.K.
Apr. 2003	Executive Officer and General Manager, Business Development Department, Eli Lilly Japan K.K.
Nov. 2008	Joined Shionogi & Co., Ltd. as General Manager, Overseas Business Promotion Department
Oct. 2017	Full-time Outside Audit & Supervisory Board Member, StemRIM Inc. (incumbent)

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.

Management & Administrator Dept.

E-Mail: stemrim-ir@stemrim.com

X: [@StemRIM_Inc](#)

For more information, please visit the StemRIM website (<https://stemrim.com/english/>)